ZA200903950B - Antibacterial quinoline derivatives - Google Patents

Antibacterial quinoline derivatives

Info

Publication number
ZA200903950B
ZA200903950B ZA200903950A ZA200903950A ZA200903950B ZA 200903950 B ZA200903950 B ZA 200903950B ZA 200903950 A ZA200903950 A ZA 200903950A ZA 200903950 A ZA200903950 A ZA 200903950A ZA 200903950 B ZA200903950 B ZA 200903950B
Authority
ZA
South Africa
Prior art keywords
quinoline derivatives
antibacterial quinoline
antibacterial
derivatives
quinoline
Prior art date
Application number
ZA200903950A
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
David Francis Alain Lancois
Ismet Dorange
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200903950(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200903950B publication Critical patent/ZA200903950B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
ZA200903950A 2006-12-06 2009-06-05 Antibacterial quinoline derivatives ZA200903950B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06

Publications (1)

Publication Number Publication Date
ZA200903950B true ZA200903950B (en) 2010-08-25

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903950A ZA200903950B (en) 2006-12-06 2009-06-05 Antibacterial quinoline derivatives

Country Status (33)

Country Link
US (1) US8415475B2 (ru)
EP (1) EP2099758B1 (ru)
JP (1) JP5466011B2 (ru)
KR (1) KR101490222B1 (ru)
CN (2) CN101553470A (ru)
AP (1) AP2479A (ru)
AR (1) AR064151A1 (ru)
AU (1) AU2007328887B2 (ru)
BR (1) BRPI0720220B8 (ru)
CA (1) CA2669819C (ru)
CL (1) CL2007003514A1 (ru)
CY (1) CY1117766T1 (ru)
DK (1) DK2099758T3 (ru)
EA (1) EA016733B1 (ru)
ES (1) ES2573689T3 (ru)
HK (1) HK1208437A1 (ru)
HR (1) HRP20160585T1 (ru)
HU (1) HUE028769T2 (ru)
IL (1) IL199083A (ru)
JO (1) JO3271B1 (ru)
ME (1) ME02498B (ru)
MX (1) MX2009005978A (ru)
MY (1) MY181645A (ru)
NO (1) NO341983B1 (ru)
NZ (1) NZ576823A (ru)
PL (1) PL2099758T3 (ru)
PT (1) PT2099758E (ru)
RS (1) RS54794B1 (ru)
SI (1) SI2099758T1 (ru)
TW (1) TWI406659B (ru)
UA (1) UA100972C2 (ru)
WO (1) WO2008068267A1 (ru)
ZA (1) ZA200903950B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102110366B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
AU2013254674B2 (en) 2012-04-27 2017-02-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
WO2014062658A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EP2909189B8 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
RU2664587C1 (ru) * 2014-07-14 2018-08-21 Шанхай Цзя Тань Фарматек Ко. Лтд. Производные пиридина и их применение против микобактерий
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN107205945A (zh) * 2015-01-27 2017-09-26 詹森药业有限公司 可分散组合物
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
BR122021024097B1 (pt) * 2016-03-07 2024-04-30 The Global Alliance For Tb Drug Development, Inc Composto antibacteriano, uso do mesmo e composição farmacêutica
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
WO2019145919A1 (en) * 2018-01-29 2019-08-01 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
IL302095A (en) * 2020-10-22 2023-06-01 Lunella Biotech Inc Mitochondrial ATP inhibitors targeting the gamma subunit prevent metastasis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018326A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
UA82198C2 (ru) 2002-07-25 2008-03-25 Янссен Фармацевтика Н.В. Хинолиновые производные и их использование в качестве микобактериальных ингибиторов, способ их получения, фармацевтическая композиция на их основе, промежуточное соединение
NZ547277A (en) 2004-01-23 2009-08-28 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors
BRPI0507065B8 (pt) * 2004-01-23 2021-05-25 Janssen Pharmaceutica Nv derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
UA83875C2 (ru) 2004-01-29 2008-08-26 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
HUE033609T2 (en) 2004-09-28 2017-12-28 Janssen Pharmaceutica Nv Bacterial ATP synthase binding domain
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
AU2007328887A1 (en) 2008-06-12
ES2573689T3 (es) 2016-06-09
PT2099758E (pt) 2016-06-02
NO341983B1 (no) 2018-03-05
CL2007003514A1 (es) 2008-07-11
IL199083A0 (en) 2010-03-28
EA200970535A1 (ru) 2009-10-30
KR101490222B1 (ko) 2015-02-05
BRPI0720220B8 (pt) 2021-05-25
CA2669819C (en) 2016-08-30
HK1208437A1 (en) 2016-03-04
CN101553470A (zh) 2009-10-07
HRP20160585T1 (hr) 2016-06-17
EA016733B1 (ru) 2012-07-30
NO20092542L (no) 2009-08-25
PL2099758T3 (pl) 2016-08-31
CA2669819A1 (en) 2008-06-12
MX2009005978A (es) 2009-06-16
TWI406659B (zh) 2013-09-01
KR20090086604A (ko) 2009-08-13
WO2008068267A1 (en) 2008-06-12
DK2099758T3 (en) 2016-06-13
BRPI0720220A2 (pt) 2013-12-24
TW200838528A (en) 2008-10-01
EP2099758A1 (en) 2009-09-16
MY181645A (en) 2020-12-30
EP2099758B1 (en) 2016-03-09
BRPI0720220B1 (pt) 2020-06-09
CY1117766T1 (el) 2017-05-17
NZ576823A (en) 2012-01-12
CN104744361B (zh) 2021-06-08
UA100972C2 (ru) 2013-02-25
SI2099758T1 (sl) 2016-07-29
AR064151A1 (es) 2009-03-18
US20100048566A1 (en) 2010-02-25
AU2007328887B2 (en) 2013-01-17
JP2010511668A (ja) 2010-04-15
ME02498B (me) 2017-02-20
AP2009004874A0 (en) 2009-06-30
JP5466011B2 (ja) 2014-04-09
AP2479A (en) 2012-09-27
JO3271B1 (ar) 2018-09-16
IL199083A (en) 2014-08-31
US8415475B2 (en) 2013-04-09
RS54794B1 (sr) 2016-10-31
HUE028769T2 (en) 2017-01-30
CN104744361A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
HK1208437A1 (en) Antibacterial quinoline derivatives
IL193265A0 (en) Quinoline derivatives
HK1137441A1 (en) Antibacterial quinoline derivatives
ZA200800783B (en) Antibacterial quinoline derivatives
IL241548B (en) Antibacterial quinoline derivatives
IL199084A0 (en) Antibacterial quinoline derivatives
HK1137428A1 (en) Antibacterial quinoline derivatives
HK1137437A1 (en) Antibacterial quinoline derivatives
ZA200806877B (en) Quinoline Derivatives